HRP20120876T1 - Brzo disocirajuä†i antagonisti dopamin 2 receptora - Google Patents
Brzo disocirajuä†i antagonisti dopamin 2 receptora Download PDFInfo
- Publication number
- HRP20120876T1 HRP20120876T1 HRP20120876AT HRP20120876T HRP20120876T1 HR P20120876 T1 HRP20120876 T1 HR P20120876T1 HR P20120876A T HRP20120876A T HR P20120876AT HR P20120876 T HRP20120876 T HR P20120876T HR P20120876 T1 HRP20120876 T1 HR P20120876T1
- Authority
- HR
- Croatia
- Prior art keywords
- 4alkyl
- halo
- substituents
- independently selected
- group
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
- 229960003638 dopamine Drugs 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 claims 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 15
- 125000001424 substituent group Chemical group 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- -1 C1-4alkyloxy Chemical group 0.000 claims 8
- 125000001544 thienyl group Chemical group 0.000 claims 8
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- 208000028017 Psychotic disease Diseases 0.000 claims 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000001041 indolyl group Chemical group 0.000 claims 4
- 125000001624 naphthyl group Chemical group 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 208000020925 Bipolar disease Diseases 0.000 claims 3
- 206010012289 Dementia Diseases 0.000 claims 3
- 208000019022 Mood disease Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 208000022821 personality disease Diseases 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- CUJPFPXNDSIBPG-UHFFFAOYSA-N 1,3-propanediyl Chemical group [CH2]C[CH2] CUJPFPXNDSIBPG-UHFFFAOYSA-N 0.000 claims 1
- YWJLFMLMZBIPMS-UHFFFAOYSA-N 4-phenyl-6-piperazin-1-yl-3-(trifluoromethyl)pyridazine Chemical compound FC(F)(F)C1=NN=C(N2CCNCC2)C=C1C1=CC=CC=C1 YWJLFMLMZBIPMS-UHFFFAOYSA-N 0.000 claims 1
- FZXQUCVBYYNHFX-UHFFFAOYSA-N 4-phenyl-6-piperazin-1-yl-3-(trifluoromethyl)pyridazine;hydrochloride Chemical compound Cl.FC(F)(F)C1=NN=C(N2CCNCC2)C=C1C1=CC=CC=C1 FZXQUCVBYYNHFX-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000031091 Amnestic disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 claims 1
- 208000021465 Brief psychotic disease Diseases 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000012202 Pervasive developmental disease Diseases 0.000 claims 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims 1
- 208000030988 Schizoid Personality disease Diseases 0.000 claims 1
- 208000019568 Shared Paranoid disease Diseases 0.000 claims 1
- 208000028810 Shared psychotic disease Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 230000006999 cognitive decline Effects 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 208000026725 cyclothymic disease Diseases 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 208000035548 disruptive behavior disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 201000002545 drug psychosis Diseases 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000006513 pyridinyl methyl group Chemical group 0.000 claims 1
- 208000022610 schizoaffective disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000000698 schizophrenic effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 208000016686 tic disease Diseases 0.000 claims 1
- 208000002271 trichotillomania Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (10)
1. Spoj formule (I)
[image]
ili njegov stereoizomerni oblik, naznačen time da
R1 je kloro, trifluorometil ili cijano;
R2 je fenil; fenil supstituiran sa 1, 2 ili 3 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo, cijano, C1-4alkil, C1-4alkiloksi, C1-4alkilsulfonil, perfluoroC1-4alkil, perfluoroC1-4alkiloksi, diC1-4alkilamino, hidroksil, i fenil proizvoljno supstituiran sa 1, 2 ili 3 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo, C1-4alkil i perfluoroC1-4alkil; tienil; tienil supstituiran sa 1 ili 2 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo i C1-4alkil; naftil; piridinil; pirolil; benzotiazolil; indolil; kinolinil; C3-8cikloalkil; ili C5-7cikloalkenil;
R3 je vodik, C1-4alkil, C1-4alkiloksi ili halo;
R4 i R5 su svaki nezavisno vodik ili C1-4alkil, ili R4 i R5 zajedno tvore C1-4alkandiil;
n je 1 ili 2; i
R6 je vodik, C1-4alkil, hidroksiC2-4alkil, C3-6cikloalkil, C3-6cikloalkil-C1-4alkil, piridinilmetil, ili fenilmetil proizvoljno supstituiran na fenilu sa 1, 2 ili 3 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo, cijano, C1-4alkil, C1-4alkiloksi, C1-4alkilsulfonil, perfluoroC1-4alkil, perfluoroC1-4alkiloksi i diC1-4alkilamino ; ili R5 i R6 zajedno tvore C2-5alkandiil;
ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
2. Spoj prema zahtjevu 1 naznačen time da
R1 je kloro, trifluorometil ili cijano;
R2 je fenil; fenil supstituiran sa 1, 2 ili 3 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo, cijano, C1-4alkil, C1-4alkiloksi, C1-4alkilsulfonil, perfluoroC1-4alkil, perfluoroC1-4alkiloksi, diC1-4alkilamino, hidroksil, i fenil supstituiran sa 1, 2 ili 3 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo, C1-4alkil i perfluoroC1-4alkil; tienil; tienil supstituiran sa 1 ili 2 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo i C1-4alkil; naftil; piridinil; pirolil; benzotiazolil; indolil; kinolinil; C3-8cikloalkil; ili C5-7cikloalkenil;
R3 je vodik, C1-4alkil ili halo;
R4 i R5 su svaki nezavisno vodik ili C1-4alkil, ili R4 i R5 zajedno tvore C1-4alkandiil;
n je 1 ili 2; i
R6 je vodik, C1-4alkil, hidroksiC2-4alkil, C3-6cikloalkil, C3-6cikloalkilC1-4alkil, ili fenilmetil supstituiran na fenilu sa 1, 2 ili 3 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo, cijano, C1-4alkil, C1-4alkiloksi, C1-4alkilsulfonil, perfluoroC1-4alkil, perfluoroC1-4alkiloksi i diC1-4alkilamino ; ili R5 i R6 zajedno tvore C2-5alkandiil;
ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
3. Spoj prema zahtjevu 1 naznačen time da
R1 je trifluorometil ili cijano;
R2 je fenil; fenil supstituiran sa 1, 2 ili 3 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo, cijano, C1-4alkil, C1-4alkiloksi, C1-4alkilsulfonil, perfluoroC1-4alkil, diC1-4alkilamino, hidroksil, i fenil supstituiran sa 1, 2 ili 3 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo, C1-4alkil i perfluoroC1-4alkil; tienil; tienil supstituiran sa 1 ili 2 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo i C1-4alkil; naftil; piridinil; pirolil; benzotiazolil; indolil; kinolinil; C3-8cikloalkil; ili C5-7cikloalkenil;
R3 je vodik;
R4 i R5 su svaki nezavisno vodik ili C1-4alkil;
n je 1;
R6 je vodik, metil, etil, ciklopropil, ili fenilmetil supstituiran na fenilu sa 1, 2 ili 3 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo, cijano, C1-4alkil, C1-4alkiloksi, C1-4alkilsulfonil, perfluoroC1-4alkil i diC1-4alkilamino ; ili R5 i R6 zajedno tvore C2-5alkandiil;
ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
4. Spoj prema zahtjevu 1 naznačen time da
R1 je trifluorometil;
R2 je fenil; fenil supstituiran sa 1, 2 ili 3 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo, cijano, C1-4alkil, C1-4alkiloksi, C1-4alkilsulfonil, perfluoroC1-4alkil, diC1-4alkilamino, hidroksil, i fenil supstituiran sa 1, 2 ili 3 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo, C1-4alkil i perfluoroC1-4alkil; tienil; tienil supstituiran sa 1 ili 2 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo i C1-4alkil; naftil; piridinil; pirolil; benzotiazolil; indolil; kinolinil; C3-8cikloalkil; ili C5-7cikloalkenil;
R3 je vodik;
R4 i R5 su svaki nezavisno vodik ili metil;
n je 1;
R6 je vodik, etil ili (3,5-difluorofenil)metil; ili
R5 i R6 zajedno tvore 1,3-propandiil;
ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
5. Spoj prema zahtjevu 1 naznačen time da spoj je 4-fenil-6-piperazin-1-il-3-trifluorometil-piridazin.
6. Spoj prema zahtjevu 1 naznačen time da spoj je 4-fenil-6-piperazin-1-il-3-trifluorometil-piridazin monohidroklorid.
7. Farmaceutski pripravak naznačen time da sadrži terapeutski učinkovitu količinu spoja kako je definirano u zahtjevu 1.
8. Spoj kako je definiran u zahtjevu 1 naznačen time da je za uporabu kao lijek.
9. Spoj kako je definiran u zahtjevu 8 naznačen time da je za uporabu kao antipsihotik.
10. Spoj kako je definiran u zahtjevu 8 naznačen time da je za uporabu kao lijek kod liječenja ili sprečavanja shizofrenije; poremećaja shizofrenog oblika; shizoafektivnog poremećaja; sumanutog poremećaja; kratkog psihotičnog poremećaja; dijeljenog psihotičnog poremećaja; psihotičnog poremećaja zbog općeg zdravstvenog stanja; psihotičnog poremećaja izazvanog drogama; psihotičnog poremećaja koji nije drugačije definiran; psihoze povezane s demencijom; teškog depresivnog poremećaja; distimije; predmenstrualnog disforičnog poremećaja; depresivnog poremećaja koji nije drugačije definiran; bipolarnog poremećaja I; bipolarnog poremećaja II; ciklotimije; bipolarnog poremećaja koji nije drugačije definiran; poremećaja raspoloženja zbog općeg zdravstvenog stanja; poremećaja raspoloženja izazvanog drogom; poremećaja raspoloženja koji nije drugačije definiran; općeg anksioznog poremećaja; opsesivno-kompulzivnog poremećaja; paničnog poremećaja; akutnog stresnog poremećaja; post-traumatskog stresnog poremećaja; mentalne zaostalosti; pervazivnih razvojnih poremećaja; poremećaja pažnje; poremećaja pažnje/hiperaktivnosti; poremećaja narušenog ponašanja; poremećaja osobnosti paranoidnog tipa; poremećaja osobnosti shizoidnog oblika; poremećaja osobnosti od shizotipičnog oblika; poremećaja sa tikovima; Touretteovog sindroma; ovisnosti o supstancama; zlouporabe supstanci; odvikavanja od supstanci; trikotilomanije; te stanja gdje je narušena spoznaja; Alzheimerove bolesti; Parkinsonove bolesti; Huntingdonove bolesti; Lewy Body demencije; demencija zbog HIV-a; demencije zbog Creutzfeldt-Jakobove bolesti; amnestičnih poremećaja; blagog kognitivnog poremećaja; senilnog spoznajnog propadanja; poremećaja hranjenja kao što su anoreksija i bulimija; te pretilost.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07102222 | 2007-02-13 | ||
PCT/EP2008/051597 WO2008098892A1 (en) | 2007-02-13 | 2008-02-11 | Fast dissociating dopamine 2 receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20120876T1 true HRP20120876T1 (hr) | 2012-11-30 |
Family
ID=38057298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20120876AT HRP20120876T1 (hr) | 2007-02-13 | 2012-10-30 | Brzo disocirajuä†i antagonisti dopamin 2 receptora |
Country Status (31)
Country | Link |
---|---|
US (2) | US8791120B2 (hr) |
EP (1) | EP2121630B1 (hr) |
JP (1) | JP5225292B2 (hr) |
KR (1) | KR101486408B1 (hr) |
CN (1) | CN101605764B (hr) |
AR (1) | AR065333A1 (hr) |
AU (1) | AU2008214716B2 (hr) |
BR (1) | BRPI0807492A2 (hr) |
CA (1) | CA2674752C (hr) |
CL (1) | CL2008000440A1 (hr) |
CY (1) | CY1113759T1 (hr) |
DK (1) | DK2121630T3 (hr) |
EA (1) | EA017508B1 (hr) |
ES (1) | ES2392470T3 (hr) |
HR (1) | HRP20120876T1 (hr) |
IL (1) | IL200310A (hr) |
JO (1) | JO2849B1 (hr) |
MX (1) | MX2009008616A (hr) |
MY (1) | MY148899A (hr) |
NZ (1) | NZ578560A (hr) |
PA (1) | PA8768901A1 (hr) |
PE (1) | PE20081665A1 (hr) |
PL (1) | PL2121630T3 (hr) |
PT (1) | PT2121630E (hr) |
RS (1) | RS52515B (hr) |
SG (1) | SG178779A1 (hr) |
SI (1) | SI2121630T1 (hr) |
TW (1) | TWI424847B (hr) |
UA (1) | UA97826C2 (hr) |
UY (1) | UY30910A1 (hr) |
WO (1) | WO2008098892A1 (hr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
JO2642B1 (en) | 2006-12-08 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
JO2849B1 (en) | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
DE102007007440A1 (de) | 2007-02-15 | 2008-08-21 | Bayerische Motoren Werke Aktiengesellschaft | Verfahren zur Steuerung und/oder Regelung der Verdampfertemperatur einer Klimaanlage in einem Kraftfahrzeug |
DK2148873T3 (da) * | 2007-04-23 | 2012-11-26 | Janssen Pharmaceutica Nv | 4-alkoxypyridazinderivater som hurtigt dissocierende dopamin 2- receptorantagonister |
AU2008240729B2 (en) | 2007-04-23 | 2012-08-23 | Janssen Pharmaceutica N.V. | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists |
EP2148872A1 (en) * | 2007-04-23 | 2010-02-03 | Janssen Pharmaceutica, N.V. | Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists |
ES2398625T3 (es) * | 2008-07-03 | 2013-03-20 | Janssen Pharmaceutica N.V. | 6-(1-Piperazinil)-piritazinas sustituidas como antagonistas de receptores 5-HT6 |
US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
ES2622161T3 (es) | 2008-07-31 | 2017-07-05 | Janssen Pharmaceutica, N.V. | Piridinas sustituidas con piperazin-1-il-trifluorometilo como antagonistas del receptor de la dopamina 2 de disociación rápida |
EP2536283B8 (en) * | 2010-02-18 | 2015-11-04 | vTv Therapeutics LLC | Phenyl-heteroaryl derivatives and methods of use thereof |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3933823A (en) * | 1971-03-29 | 1976-01-20 | E. R. Squibb & Sons, Inc. | Isoxazolopyridine ketone derivatives |
DE2341965C3 (de) * | 1973-08-20 | 1979-01-25 | C.H. Boehringer Sohn, 6507 Ingelheim | 4- [N- (o-PyridyD- N-acyl] -aminolphenäthylpiperidine, Verfahren zu deren Herstellung sowie deren Verwendung bei der Bekämpfung von Schmerzzuständen |
US4197304A (en) * | 1975-09-23 | 1980-04-08 | Janssen Pharmaceutica N.V. | N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides |
NO147672C (no) | 1975-09-23 | 1983-05-25 | Janssen Pharmaceutica Nv | Analogifremgangsmaate for fremstilling av n-aryl-n-(1-l1-4-piperidinyl)-arylacetamider |
EG12406A (en) * | 1976-08-12 | 1979-03-31 | Janssen Pharmaceutica Nv | Process for preparing of novel n-aryl-n-(1-l-4-piperidinyl)-arylacetamides |
DE3218482A1 (de) * | 1982-05-15 | 1983-11-17 | Bayer Ag, 5090 Leverkusen | Substituierte 5-trifluormethyl-1,3,4-thiadiazol-2-yloxyessigsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
ES8802151A1 (es) | 1985-07-31 | 1988-04-01 | Janssen Pharmaceutica Nv | Un procedimiento para la preparacion de nuevos piridazinaminas. |
MX173362B (es) * | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
US5461053A (en) * | 1989-02-07 | 1995-10-24 | Sanofi | Pyridazine derivatives |
PT93060B (pt) | 1989-02-07 | 1995-12-29 | Sanofi Sa | Processo para a obtencao de derivados de piridazina e de composicoes farmaceuticas que os contem |
GB9216298D0 (en) | 1991-08-15 | 1992-09-16 | Ici Plc | Piperidine derivatives |
CA2176722A1 (en) | 1993-12-28 | 1995-07-06 | Ruth E. Ten Brink | Heterocyclic compounds for the treatment of cns and cardiovascular disorders |
DE4425145A1 (de) * | 1994-07-15 | 1996-01-18 | Basf Ag | Verwendung von Thiazol- und Thiadiazolverbindungen |
TW406075B (en) | 1994-12-13 | 2000-09-21 | Upjohn Co | Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds |
US5560931A (en) * | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
US5753679A (en) | 1995-05-10 | 1998-05-19 | Hoffmann-La Roche Inc. | Benzyl-piperidine derivatives |
MY116093A (en) * | 1996-02-26 | 2003-11-28 | Upjohn Co | Azolyl piperazinyl phenyl oxazolidinone antimicrobials |
TW504510B (en) | 1996-05-10 | 2002-10-01 | Janssen Pharmaceutica Nv | 2,4-diaminopyrimidine derivatives |
BR9811557A (pt) * | 1997-08-15 | 2000-08-22 | Pfizer Prod Inc | Derivados do 2-)4-aril ou heteroaril-piperazin-1-ilmetil)-1h-indol |
KR100261139B1 (ko) | 1998-01-16 | 2000-08-01 | 황준수 | 신규한 알릴티오피리다진 유도체 및 그의 제조방법 |
AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
UA75392C2 (en) | 2001-02-23 | 2006-04-17 | Merck & Co Inc | N-substituted non-aryl heterocyclic antagonists nmda/nr2b |
ATE417845T1 (de) | 2001-10-09 | 2009-01-15 | Kyorin Seiyaku Kk | Neue 4-(2-furoyl)-amino-piperidine, zwischenprodukte für deren synthese, verfahren zu deren herstellung und deren medizinische verwendung |
GB0127832D0 (en) | 2001-11-20 | 2002-01-09 | Jagotec Ag | Method for the preparation of pharmaceutical nanosuspensions |
WO2003049736A1 (en) | 2001-12-11 | 2003-06-19 | Sepracor, Inc. | 4-substituted piperidines, and methods of use thereof |
EP1467981A1 (en) | 2002-01-25 | 2004-10-20 | Kylix Pharmaceuticals B.V. | 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2 |
AU2003203148A1 (en) * | 2002-02-05 | 2003-09-02 | High Point Pharmaceuticals, Llc | Novel aryl- and heteroarylpiperazines |
US20030236259A1 (en) * | 2002-02-05 | 2003-12-25 | Rolf Hohlweg | Novel aryl- and heteroarylpiperazines |
WO2003072548A1 (en) | 2002-02-22 | 2003-09-04 | Pharmacia & Upjohn Company | Pyridyl sulfone derivatives as 5-ht receptor antagonists |
SE0201544D0 (sv) | 2002-05-17 | 2002-05-17 | Biovitrum Ab | Novel compounds and thier use |
WO2004028520A1 (ja) * | 2002-09-26 | 2004-04-08 | Mandom Corporation | 防腐殺菌剤並びに該防腐殺菌剤を配合した化粧料、医薬品及び食品 |
ES2211344B1 (es) | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
CA2518823A1 (en) | 2003-03-24 | 2004-10-07 | F.Hoffmann-La Roche Ag | Benzyl-pyridazinons as reverse transcriptase inhibitors |
DE50312980D1 (de) * | 2003-05-07 | 2010-09-23 | Kemira Pigments Oy | Ftstoffen und aromen |
KR101160858B1 (ko) | 2003-05-08 | 2012-07-02 | 가부시끼가이샤 닛신 세이훈 그룹 혼샤 | 소양 치료약으로서 유용한 4-(2-푸로일)아미노피페리딘류 |
WO2005005779A2 (en) | 2003-07-14 | 2005-01-20 | Genesis Mining Technologies (Pty) Ltd | Dual retention cutting arrangement |
MXPA06001053A (es) | 2003-07-29 | 2006-04-11 | Novo Nordisk As | Piridazinil-piperazinas y su uso como ligandos del receptor de histamina h3. |
EP3042895A1 (en) * | 2003-07-30 | 2016-07-13 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
WO2005013907A2 (en) | 2003-08-07 | 2005-02-17 | Japan Tobacco Inc. | Pyrrolo[1,2-b]pyridazine derivatives |
US7863044B2 (en) | 2003-10-24 | 2011-01-04 | Tao Cheng | p18 in stem cell manipulations |
AR047537A1 (es) | 2004-02-10 | 2006-01-25 | Janssen Pharmaceutica Nv | Piridazinonaureas como antagonistas de integrinas |
CN1934092A (zh) | 2004-03-23 | 2007-03-21 | 弗·哈夫曼-拉罗切有限公司 | 非核苷逆转录酶抑制剂 |
BRPI0510340A (pt) | 2004-04-28 | 2007-10-30 | Pfizer | derivados de 3-heterociclil-4-feniltriazol como inibidores do receptor via da vasopressina |
AU2005249494A1 (en) * | 2004-05-28 | 2005-12-15 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
ES2251866B1 (es) | 2004-06-18 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
ES2251867B1 (es) | 2004-06-21 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
TW200626154A (en) | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
ES2682282T3 (es) | 2004-10-29 | 2018-09-19 | Kalypsys, Inc. | Compuestos bicíclicos sustituidos con sulfonilo como moduladores de PPAR |
JP2008534640A (ja) * | 2005-04-05 | 2008-08-28 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | タンパク質の機能部位またはエピトープの遮蔽方法 |
CN101243072A (zh) | 2005-06-20 | 2008-08-13 | 先灵公司 | 用作组胺h3拮抗剂的哌啶衍生物 |
JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
WO2007130383A2 (en) * | 2006-04-28 | 2007-11-15 | Northwestern University | Compositions and treatments using pyridazine compounds and secretases |
US7754744B2 (en) | 2006-08-15 | 2010-07-13 | Hoffmann-La Roche Inc. | Substituted piperidinamines as somatostatin receptor subtype 5 (SSTR5) antagonists |
US8058243B2 (en) * | 2006-10-13 | 2011-11-15 | Hsc Research And Development Limited Partnership | Method for treating a brain cancer with ifenprodil |
JO2642B1 (en) * | 2006-12-08 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
TW200829566A (en) | 2006-12-08 | 2008-07-16 | Astrazeneca Ab | Chemical compounds |
JO2849B1 (en) | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
DK2148873T3 (da) * | 2007-04-23 | 2012-11-26 | Janssen Pharmaceutica Nv | 4-alkoxypyridazinderivater som hurtigt dissocierende dopamin 2- receptorantagonister |
AU2008240729B2 (en) * | 2007-04-23 | 2012-08-23 | Janssen Pharmaceutica N.V. | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists |
EP2148872A1 (en) * | 2007-04-23 | 2010-02-03 | Janssen Pharmaceutica, N.V. | Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists |
PE20091194A1 (es) * | 2007-09-20 | 2009-09-05 | Glaxo Group Ltd | Derivados de heterociclicos como moduladores del receptor m1 |
ES2398625T3 (es) * | 2008-07-03 | 2013-03-20 | Janssen Pharmaceutica N.V. | 6-(1-Piperazinil)-piritazinas sustituidas como antagonistas de receptores 5-HT6 |
ES2622161T3 (es) | 2008-07-31 | 2017-07-05 | Janssen Pharmaceutica, N.V. | Piridinas sustituidas con piperazin-1-il-trifluorometilo como antagonistas del receptor de la dopamina 2 de disociación rápida |
-
2008
- 2008-02-02 JO JO200832A patent/JO2849B1/en active
- 2008-02-11 PT PT08716791T patent/PT2121630E/pt unknown
- 2008-02-11 SI SI200830804T patent/SI2121630T1/sl unknown
- 2008-02-11 MY MYPI20093319A patent/MY148899A/en unknown
- 2008-02-11 CA CA 2674752 patent/CA2674752C/en active Active
- 2008-02-11 ES ES08716791T patent/ES2392470T3/es active Active
- 2008-02-11 WO PCT/EP2008/051597 patent/WO2008098892A1/en active Application Filing
- 2008-02-11 EA EA200970760A patent/EA017508B1/ru not_active IP Right Cessation
- 2008-02-11 DK DK08716791.2T patent/DK2121630T3/da active
- 2008-02-11 KR KR20097016881A patent/KR101486408B1/ko active IP Right Grant
- 2008-02-11 MX MX2009008616A patent/MX2009008616A/es active IP Right Grant
- 2008-02-11 AU AU2008214716A patent/AU2008214716B2/en not_active Ceased
- 2008-02-11 BR BRPI0807492-5A2A patent/BRPI0807492A2/pt not_active IP Right Cessation
- 2008-02-11 UY UY30910A patent/UY30910A1/es unknown
- 2008-02-11 CN CN2008800047871A patent/CN101605764B/zh active Active
- 2008-02-11 RS RS20120468A patent/RS52515B/en unknown
- 2008-02-11 PL PL08716791T patent/PL2121630T3/pl unknown
- 2008-02-11 US US12/526,945 patent/US8791120B2/en active Active
- 2008-02-11 UA UAA200908948A patent/UA97826C2/ru unknown
- 2008-02-11 PA PA20088768901A patent/PA8768901A1/es unknown
- 2008-02-11 EP EP08716791A patent/EP2121630B1/en active Active
- 2008-02-11 PE PE2008000294A patent/PE20081665A1/es active IP Right Grant
- 2008-02-11 JP JP2009548697A patent/JP5225292B2/ja active Active
- 2008-02-11 SG SG2012009791A patent/SG178779A1/en unknown
- 2008-02-11 NZ NZ578560A patent/NZ578560A/en not_active IP Right Cessation
- 2008-02-12 CL CL200800440A patent/CL2008000440A1/es unknown
- 2008-02-12 TW TW097104844A patent/TWI424847B/zh not_active IP Right Cessation
- 2008-02-13 AR ARP080100616A patent/AR065333A1/es active IP Right Grant
-
2009
- 2009-08-10 IL IL200310A patent/IL200310A/en active IP Right Grant
-
2012
- 2012-10-30 CY CY20121101028T patent/CY1113759T1/el unknown
- 2012-10-30 HR HRP20120876AT patent/HRP20120876T1/hr unknown
-
2014
- 2014-07-28 US US14/444,968 patent/US9422296B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20120876T1 (hr) | Brzo disocirajuä†i antagonisti dopamin 2 receptora | |
HRP20211282T1 (hr) | Oksisteroli i postupci njihovog korištenja | |
HRP20110226T1 (hr) | Derivati piperidin-4-il-piridazin-3-ilamina kao brzo disocirajući antagonisti dopamin 2 receptora | |
HRP20201216T1 (hr) | PRIPRAVCI I POSTUPCI ZA LIJEČENJE POREMEĆAJA CNS-a | |
HRP20160647T1 (hr) | Novi heterociklički derivati i njihova uporaba u liječenju neuroloških poremećaja | |
HRP20170570T1 (hr) | Piperazin-1-il-trifluormetil-supstituirani-piridini kao brzo disocirajući antagonisti receptora dopamina 2 | |
HRP20120913T1 (hr) | Derivati 4-alkoksipiridazina kao brzo disocirajuä†i antagonisti dopamin 2 receptora | |
AU2014241759B2 (en) | Substituted naphthyridine and quinoline compounds as MAO inhibitors | |
MEP45308A (en) | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | |
HRP20192020T1 (hr) | Derivati heteroarila i njihova upotreba | |
HRP20050708A2 (en) | Piperidine-benzenesulfonamide derivatives | |
HRP20160030T1 (hr) | Derivati 6,7-dihidro-pirazolo[1,5-a]pirazin-4-ilamina koji su korisni kao inhibitori beta-sekretaze (bace) | |
HRP20110220T1 (hr) | Inhibitori kinaze | |
MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
ME00954B (me) | Aminoheterociklični spojevi | |
HRP20140451T1 (hr) | Derivati izoksazola i njihova uporaba kao pojaäśivaäśa metabotropnih glutamatnih receptora | |
AP2008A (en) | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders; process for their preparation and pharmaceutical compositions containing them | |
HRP20141199T1 (hr) | Kombinacija od spoja glyt1 s antipsihoticima | |
UY30408A1 (es) | Derivados sustituidos del acetato de 8-(4-metoxifenil)-2,3,4,8-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones | |
HRP20141108T1 (hr) | Antagonisti piperidinon karboksamid azaindan cgrp receptora | |
WO2008080844A9 (en) | Azaspiro derivatives | |
JP2014507455A5 (hr) | ||
MX2010005753A (es) | Derivados de isoxazolo-pirazina. | |
TW200630371A (en) | Halogen substituted benzodiazepine derivatives | |
BRPI0408591A (pt) | derivados de 6,7,8,9-tetrahidropirimido[1,2-a] pirimidin-4-ona 8-substituìda |